NVO [NYSE]
Novo Nordisk A/S
Index- P/E34.51 EPS (ttm)2.99 Insider Own26.40% Shs Outstand2.28B Perf Week-2.83%
Market Cap177.30B Forward P/E3.82 EPS next Y27.04 Insider Trans0.00% Shs Float1.11B Perf Month-12.66%
Income6.88B PEG2.40 EPS next Q5.88 Inst Own7.80% Short Float0.16% Perf Quarter5.20%
Sales20.79B P/S8.53 EPS this Y15.20% Inst Trans1.56% Short Ratio1.18 Perf Half Y-8.72%
Book/sh4.08 P/B25.30 EPS next Y13.81% ROA27.30% Target Price132.30 Perf Year28.12%
Cash/sh1.64 P/C63.08 EPS next 5Y14.40% ROE73.40% 52W Range78.71 - 122.16 Perf YTD-7.82%
Dividend1.57 P/FCF34.20 EPS past 5Y6.70% ROI48.60% 52W High-15.49% Beta0.51
Dividend %1.52% Quick Ratio0.70 Sales past 5Y4.70% Gross Margin83.40% 52W Low31.17% ATR3.16
Employees49295 Current Ratio0.90 Sales Q/Q24.30% Oper. Margin42.10% RSI (14)36.95 Volatility2.47% 2.33%
OptionableYes Debt/Eq0.38 EPS Q/Q14.20% Profit Margin33.10% Rel Volume1.30 Prev Close106.04
ShortableYes LT Debt/Eq0.36 Earnings- Payout312.60% Avg Volume1.47M Price103.24
Recom2.00 SMA20-6.99% SMA50-6.70% SMA200-2.26% Volume1,893,249 Change-2.64%
Apr-25-22Upgrade Cowen Market Perform → Outperform $130
Apr-12-22Upgrade Morgan Stanley Underweight → Equal-Weight
Mar-16-22Upgrade Deutsche Bank Hold → Buy
Jan-25-22Downgrade Liberum Hold → Sell
Dec-20-21Downgrade JP Morgan Overweight → Neutral
Dec-17-21Downgrade Deutsche Bank Buy → Hold
Jan-20-21Downgrade Credit Suisse Outperform → Neutral
Jan-15-21Initiated Deutsche Bank Buy
Sep-29-20Initiated Berenberg Hold
Jul-06-20Downgrade BofA Securities Buy → Neutral
May-11-20Downgrade UBS Buy → Neutral
May-04-20Initiated Cowen Market Perform $72
Mar-16-20Upgrade BofA/Merrill Neutral → Buy
Jan-03-20Downgrade Guggenheim Buy → Neutral
Nov-18-19Upgrade Barclays Equal Weight → Overweight
Sep-17-19Upgrade Citigroup Neutral → Buy
Aug-30-19Downgrade Jefferies Hold → Underperform
Jun-20-19Downgrade Deutsche Bank Buy → Hold
Jun-11-19Upgrade Barclays Underweight → Equal Weight
Apr-29-19Upgrade Credit Suisse Neutral → Outperform
May-16-22 04:08PM  
10:04AM  
09:28AM  
May-14-22 12:20PM  
May-13-22 12:26PM  
May-12-22 05:24AM  
May-11-22 09:27AM  
May-07-22 07:03AM  
May-06-22 12:24PM  
11:26AM  
05:20AM  
May-03-22 01:31PM  
01:24PM  
01:18PM  
10:11AM  
08:16AM  
May-02-22 11:07AM  
11:04AM  
10:11AM  
06:22AM  
Apr-29-22 12:30PM  
07:43AM  
07:08AM  
05:14AM  
03:27AM  
02:47AM  
02:39AM  
Apr-28-22 10:54AM  
10:36AM  
10:36AM  
Apr-27-22 08:03AM  
06:39AM  
Apr-26-22 05:20PM  
02:57PM  
Apr-25-22 10:07AM  
Apr-23-22 08:42AM  
Apr-22-22 05:39AM  
Apr-20-22 03:22PM  
Apr-13-22 03:00AM  
Apr-11-22 02:17PM  
12:52PM  
08:11AM  
Apr-07-22 10:27AM  
Apr-04-22 06:39AM  
Mar-31-22 08:26PM  
Mar-30-22 10:41AM  
Mar-29-22 03:55PM  
11:28AM  
Mar-28-22 05:53PM  
05:41PM  
08:49AM  
Mar-24-22 11:00AM  
10:55AM  
10:38AM  
Mar-21-22 12:22PM  
08:15AM  
Mar-16-22 10:45AM  
Mar-14-22 10:51AM  
08:12AM  
Mar-10-22 09:03AM  
Mar-08-22 11:40AM  
Mar-07-22 09:05AM  
08:08AM  
Mar-04-22 10:57AM  
Mar-03-22 07:00AM  
07:00AM  
02:00AM  
01:00AM  
Mar-01-22 05:21PM  
11:11AM  
Feb-28-22 12:06PM  
09:45AM  
05:03AM  
Feb-25-22 12:46PM  
Feb-21-22 10:21AM  
09:05AM  
06:09AM  
Feb-18-22 10:05AM  
Feb-14-22 09:48AM  
06:37AM  
Feb-11-22 10:33AM  
Feb-09-22 10:19AM  
Feb-08-22 10:10AM  
06:20AM  
Feb-07-22 10:40AM  
Feb-05-22 11:45AM  
Feb-04-22 05:38PM  
11:46AM  
10:16AM  
Feb-02-22 12:48PM  
09:35AM  
07:39AM  
01:44AM  
01:30AM  
Feb-01-22 12:26PM  
09:45AM  
Jan-31-22 05:28AM  
Jan-28-22 09:38AM  
Jan-26-22 05:38PM  
Jan-25-22 09:38AM  
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.